Qyuns Therapeutics Co., Ltd. (HKG:2509)

Hong Kong · Delayed Price · Currency is HKD

17.02

-0.18 (-1.05%)

May 7, 2026, 4:08 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Biologic Therapies for Autoimmune and Allergic Diseases	806.96M	158.79M	-	9.66M	21.35M
Biologic Therapies for Autoimmune and Allergic Diseases Growth	408.18%	-	-	-54.74%	-
Total	806.96M	158.79M	-	9.66M	21.35M
Total Growth	408.18%	-	-	-54.74%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
The People's Republic of China (The "PRC")	104.56M	158.79M	-	9.66M	21.35M
The People's Republic of China (The "PRC") Growth	-34.15%	-	-	-54.74%	-
The United States	197.80M	-	-	-	-
Switzerland	504.60M	-	-	-	-
Total	806.96M	158.79M	-	9.66M	21.35M
Total Growth	408.18%	-	-	-54.74%	-

Source: S&P Global Market Intelligence.